수막염균 백신 시장 규모, 점유율, 성장 분석 : 백신 유형별, 브랜드별, 연령층별, 최종사용자별, 지역별 - 산업 예측(2024-2031년)

Global Meningococcal Vaccines Market size was valued at USD 4.30 billion in 2022 and is poised to grow from USD 4.58 billion in 2023 to USD 7.58 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).

The meningococcal vaccines market is poised for significant growth, driven by the rising incidence of meningitis, with an estimated 1.2 million cases globally, as reported by the CDC. Enhanced immunization initiatives, heightened public awareness, and intensified research and development activities surrounding meningococcal vaccines are expected to further bolster market expansion. Numerous campaigns led by organizations like the National Meningitis Association and the Meningitis Research Foundation are raising awareness and promoting innovative prevention strategies. The market features various vaccines targeting Neisseria meningitidis, including monovalent and multivalent options against strains A, B, C, W-135, and Y. Additionally, the increasing integration of these vaccines into national immunization programs and the growth of travel vaccination availability are key factors influencing market dynamics, despite potential challenges from strict regulatory measures.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Meningococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Meningococcal Vaccines Market Segmental Analysis

Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Meningococcal Vaccines Market

A significant factor propelling the global meningococcal vaccines market is the growing incidence of meningococcal diseases worldwide. The emergence of meningitis and septicemia caused by Neisseria meningitidis presents a serious health threat, resulting in high mortality rates and potential long-term consequences, including neurological damage. Consequently, healthcare providers are increasingly focusing on preventive measures, particularly vaccination, to curb these outbreaks. This concern is particularly pronounced in specific regions, such as Sub-Saharan Africa, often referred to as the "meningitis belts," where the prevalence of infections is notably higher, thereby driving the demand for effective vaccines in these vulnerable areas.

Restraints in the Global Meningococcal Vaccines Market

A significant restraint within the global meningococcal vaccines market is the prohibitively high production and distribution costs. The advanced vaccines, particularly those utilizing conjugate and recombinant technologies, are not easily accessible in low-income regions that are disproportionately affected by meningococcal disease. Despite efforts from governmental and non-governmental organizations to provide subsidies, the overall affordability of these vaccines continues to pose a major challenge. This financial barrier ultimately limits the reach of vaccination programs, hindering efforts to achieve broad immunization coverage and protect vulnerable populations from the potentially devastating impacts of meningococcal infections.

Market Trends of the Global Meningococcal Vaccines Market

The global meningococcal vaccines market is witnessing a significant trend towards the adoption of combination vaccines, particularly quadrivalent formulations that provide protection against serogroups A, C, W, and Y. This preference is largely driven by the advantages these vaccines offer, including wider coverage and the convenience of requiring fewer doses. As healthcare systems aim to improve immunization rates and streamline vaccine administration processes, combination vaccines are becoming essential in overcoming logistical hurdles and enhancing patient adherence to vaccination schedules. This trend not only reflects a growing awareness of meningococcal disease but also represents a pivotal shift towards more effective public health strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Meningococcal Vaccines Market Size by Vaccine Type & CAGR (2024-2031)

• Market Overview
• Polysaccharide Vaccines
• Conjugate Vaccines
  • Quadrivalent
  • Bivalent
  • Monovalent
• Combination Vaccines
• Men B Vaccines

Global Meningococcal Vaccines Market Size by Brand & CAGR (2024-2031)

• Market Overview
• Menactra
• Menveo
• Nimenrix
• Bexsero
• Trumenba
• Others

Global Meningococcal Vaccines Market Size by Age Group & CAGR (2024-2031)

• Market Overview
• Infants
• Children
• Adolescents
• Adults

Global Meningococcal Vaccines Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Vaccination Centers
• Others

Global Meningococcal Vaccines Market Size & CAGR (2024-2031)

• North America (Vaccine Type, Brand, Age Group, End User)
  • US
  • Canada
• Europe (Vaccine Type, Brand, Age Group, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Vaccine Type, Brand, Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Vaccine Type, Brand, Age Group, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Brand, Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomed Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Walvax Biotechnology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Vaccine Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation